[Form 4] Labcorp Holdings Inc. Insider Trading Activity
Sandra D. van der Vaart, identified as EVP, Chief Legal Officer of Labcorp Holdings Inc. (LH), reported offsetting option exercise and share sale transactions dated 08/13/2025. She exercised 3,903 non-qualified stock options with an exercise price of $131.43 per share, resulting in the acquisition of 3,903 common shares. On the same date she sold 3,903 common shares at a reported price of $271.4249 per share. The filing shows 6,176.6691 shares beneficially owned after the acquisition line and 2,273.6691 shares after the sale line. The options were granted under the company omnibus plan, vesting began 02/12/2020 and are exercisable through 02/11/2029. An additional 30.1294 shares were included from the employee stock purchase plan.
Sandra D. van der Vaart, indicata come EVP, Chief Legal Officer di Labcorp Holdings Inc. (LH), ha comunicato operazioni compensative di esercizio di opzioni e vendita di azioni in data 13/08/2025. Ha esercitato 3.903 opzioni azionarie non qualificate con prezzo di esercizio di $131,43 per azione, acquisendo cos矛 3.903 azioni ordinarie. Nella stessa data ha venduto 3.903 azioni ordinarie a un prezzo dichiarato di $271,4249 per azione. Il documento riporta 6.176,6691 azioni possedute come beneficiarie dopo la voce di acquisizione e 2.273,6691 azioni dopo la voce di vendita. Le opzioni sono state concesse nell鈥檃mbito del piano omnibus della societ脿, la vesting 猫 iniziata il 12/02/2020 e sono esercitabili fino al 11/02/2029. Sono inoltre incluse 30,1294 azioni provenienti dal piano di acquisto azionario dei dipendenti.
Sandra D. van der Vaart, identificada como EVP, Chief Legal Officer de Labcorp Holdings Inc. (LH), inform贸 operaciones compensatorias de ejercicio de opciones y venta de acciones con fecha 13/08/2025. Ejerci贸 3.903 opciones sobre acciones no calificadas con un precio de ejercicio de $131,43 por acci贸n, adquiriendo 3.903 acciones ordinarias. En la misma fecha vendi贸 3.903 acciones ordinarias a un precio informado de $271,4249 por acci贸n. El expediente muestra 6.176,6691 acciones en propiedad beneficiaria tras la l铆nea de adquisici贸n y 2.273,6691 acciones tras la l铆nea de venta. Las opciones fueron otorgadas bajo el plan omnibus de la compa帽铆a, la consolidaci贸n (vesting) comenz贸 el 12/02/2020 y son ejercitables hasta el 11/02/2029. Adem谩s, se incluyeron 30,1294 acciones procedentes del plan de compra de acciones para empleados.
Sandra D. van der Vaart, Labcorp Holdings Inc.(LH)鞚� EVP 瓴� Chief Legal Officer搿� 鞁濍硠霅� 鞚鸽鞚� 2025-08-13鞛� 靸侅噭霅橂姅 鞓奠厴 頄夓偓 氚� 欤检嫕 毵る弰 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽厐電� 頄夓偓臧�瓴╈澊 欤茧嫻 $131.43鞚� 牍勳瀽瓴� 欤检嫕鞓奠厴 3,903欤茧ゼ 頄夓偓頃橃棳 3,903欤� 氤错喌欤茧ゼ 旆摑頄堨姷雼堧嫟. 臧欖潃 雮� 霃欖澕頃� 靾橂焿鞚� 3,903欤茧ゼ 欤茧嫻 $271.4249鞐� 毵る弰頄堨姷雼堧嫟. 氤搓碃靹滌棎電� 旆摑 頃 頉� 鞁れ 氤挫湢欤检嫕鞚� 6,176.6691欤�, 毵る弰 頃 頉勳棎電� 2,273.6691欤茧 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 鞓奠厴霌れ潃 須岇偓鞚� 鞓措媹氩勳姢 頂岆灉 頃橃棎 攵�鞐悩鞐堨溂氅�, 氩犾姢韺呾潃 2020-02-12鞐� 鞁滌瀾霅橃棃瓿� 2029-02-11旯岇 頄夓偓頃� 靾� 鞛堨姷雼堧嫟. 霕愴暅 歆侅洂 欤检嫕毵れ垬瓿勴殟鞐愳劀 30.1294欤缄皜 韽暔霅橃棃鞀惦媹雼�.
Sandra D. van der Vaart, identifi茅e en tant qu'EVP, Chief Legal Officer de Labcorp Holdings Inc. (LH), a d茅clar茅 des op茅rations compensatoires d'exercice d'options et de vente d'actions dat茅es du 13/08/2025. Elle a exerc茅 3听903 options d'achat d'actions non qualifi茅es au prix d'exercice de $131,43 par action, acqu茅rant ainsi 3听903 actions ordinaires. Le m锚me jour, elle a vendu 3听903 actions ordinaires au prix d茅clar茅 de $271,4249 par action. Le d茅p么t indique 6听176,6691 actions d茅tenues au titre de l'avantage apr猫s la ligne d'acquisition et 2听273,6691 actions apr猫s la ligne de vente. Les options ont 茅t茅 accord茅es dans le cadre du plan omnibus de la soci茅t茅, la p茅riode d'acquisition (vesting) a commenc茅 le 12/02/2020 et elles sont exer莽ables jusqu'au 11/02/2029. Sont 茅galement incluses 30,1294 actions provenant du plan d'achat d'actions pour les employ茅s.
Sandra D. van der Vaart, als EVP, Chief Legal Officer von Labcorp Holdings Inc. (LH) benannt, meldete ausgleichende Optionsaus眉bungs- und Aktienverkaufstransaktionen dated 13.08.2025. Sie 眉bte 3.903 nicht qualifizierte Aktienoptionen mit einem Aus眉bungspreis von $131,43 je Aktie aus und erwarb damit 3.903 Stammaktien. Am selben Tag verkaufte sie 3.903 Stammaktien zu einem gemeldeten Preis von $271,4249 je Aktie. Die Meldung weist 6.176,6691 beg眉nstigt gehaltene Aktien nach der Erwerbszeile und 2.273,6691 Aktien nach der Verkaufszeile aus. Die Optionen wurden im Rahmen des Omnibus-Plans des Unternehmens gew盲hrt, das Vesting begann am 12.02.2020 und die Optionen sind bis zum 11.02.2029 aus眉bbar. Zus盲tzlich wurden 30,1294 Aktien aus dem Mitarbeiter-Aktienkaufplan einbezogen.
- Exercise of 3,903 non-qualified options at a stated exercise price of $131.43, demonstrating use of vested equity awards
- Disclosure includes ESPP share credit of 30.1294 shares, reflecting participation in the employee purchase plan
- Form is signed by the reporting person, indicating a complete Section 16 filing
- Sale of 3,903 shares on the same date reduced the reporting person鈥檚 beneficial holdings to 2,273.6691 shares as shown
- No new grants or strategic rationale provided in the filing beyond automated adjustment language related to the spin-off
Insights
TL;DR: Executive exercised options and immediately sold an equal number of shares, leaving a reduced net holding.
The report documents a routine exercise of non-qualified stock options followed by an immediate sale of the same number of shares, both on 08/13/2025. The exercise price is stated at $131.43 and the sale price at $271.4249, with the option originally granted under the company omnibus incentive plan and fully exercisable. From an investor-monitoring perspective, this is a standard liquidity-management transaction by an insider and does not by itself disclose strategic corporate changes or material new information about Labcorp's operations or financial condition.
TL;DR: Filing reflects compliance with Section 16 reporting and documents an equity award adjustment tied to a prior spin-off.
The filing includes an explicit adjustment note stating amounts were automatically adjusted due to the Fortrea spin-off, calculated per an Employee Matters Agreement. It also discloses inclusion of 30.1294 ESPP shares. The form is signed and dated by the reporting person, evidencing adherence to reporting formalities. There are no disclosures of departures, new grants beyond the adjusted option, or other governance actions in this filing.
Sandra D. van der Vaart, indicata come EVP, Chief Legal Officer di Labcorp Holdings Inc. (LH), ha comunicato operazioni compensative di esercizio di opzioni e vendita di azioni in data 13/08/2025. Ha esercitato 3.903 opzioni azionarie non qualificate con prezzo di esercizio di $131,43 per azione, acquisendo cos矛 3.903 azioni ordinarie. Nella stessa data ha venduto 3.903 azioni ordinarie a un prezzo dichiarato di $271,4249 per azione. Il documento riporta 6.176,6691 azioni possedute come beneficiarie dopo la voce di acquisizione e 2.273,6691 azioni dopo la voce di vendita. Le opzioni sono state concesse nell鈥檃mbito del piano omnibus della societ脿, la vesting 猫 iniziata il 12/02/2020 e sono esercitabili fino al 11/02/2029. Sono inoltre incluse 30,1294 azioni provenienti dal piano di acquisto azionario dei dipendenti.
Sandra D. van der Vaart, identificada como EVP, Chief Legal Officer de Labcorp Holdings Inc. (LH), inform贸 operaciones compensatorias de ejercicio de opciones y venta de acciones con fecha 13/08/2025. Ejerci贸 3.903 opciones sobre acciones no calificadas con un precio de ejercicio de $131,43 por acci贸n, adquiriendo 3.903 acciones ordinarias. En la misma fecha vendi贸 3.903 acciones ordinarias a un precio informado de $271,4249 por acci贸n. El expediente muestra 6.176,6691 acciones en propiedad beneficiaria tras la l铆nea de adquisici贸n y 2.273,6691 acciones tras la l铆nea de venta. Las opciones fueron otorgadas bajo el plan omnibus de la compa帽铆a, la consolidaci贸n (vesting) comenz贸 el 12/02/2020 y son ejercitables hasta el 11/02/2029. Adem谩s, se incluyeron 30,1294 acciones procedentes del plan de compra de acciones para empleados.
Sandra D. van der Vaart, Labcorp Holdings Inc.(LH)鞚� EVP 瓴� Chief Legal Officer搿� 鞁濍硠霅� 鞚鸽鞚� 2025-08-13鞛� 靸侅噭霅橂姅 鞓奠厴 頄夓偓 氚� 欤检嫕 毵る弰 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽厐電� 頄夓偓臧�瓴╈澊 欤茧嫻 $131.43鞚� 牍勳瀽瓴� 欤检嫕鞓奠厴 3,903欤茧ゼ 頄夓偓頃橃棳 3,903欤� 氤错喌欤茧ゼ 旆摑頄堨姷雼堧嫟. 臧欖潃 雮� 霃欖澕頃� 靾橂焿鞚� 3,903欤茧ゼ 欤茧嫻 $271.4249鞐� 毵る弰頄堨姷雼堧嫟. 氤搓碃靹滌棎電� 旆摑 頃 頉� 鞁れ 氤挫湢欤检嫕鞚� 6,176.6691欤�, 毵る弰 頃 頉勳棎電� 2,273.6691欤茧 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 鞓奠厴霌れ潃 須岇偓鞚� 鞓措媹氩勳姢 頂岆灉 頃橃棎 攵�鞐悩鞐堨溂氅�, 氩犾姢韺呾潃 2020-02-12鞐� 鞁滌瀾霅橃棃瓿� 2029-02-11旯岇 頄夓偓頃� 靾� 鞛堨姷雼堧嫟. 霕愴暅 歆侅洂 欤检嫕毵れ垬瓿勴殟鞐愳劀 30.1294欤缄皜 韽暔霅橃棃鞀惦媹雼�.
Sandra D. van der Vaart, identifi茅e en tant qu'EVP, Chief Legal Officer de Labcorp Holdings Inc. (LH), a d茅clar茅 des op茅rations compensatoires d'exercice d'options et de vente d'actions dat茅es du 13/08/2025. Elle a exerc茅 3听903 options d'achat d'actions non qualifi茅es au prix d'exercice de $131,43 par action, acqu茅rant ainsi 3听903 actions ordinaires. Le m锚me jour, elle a vendu 3听903 actions ordinaires au prix d茅clar茅 de $271,4249 par action. Le d茅p么t indique 6听176,6691 actions d茅tenues au titre de l'avantage apr猫s la ligne d'acquisition et 2听273,6691 actions apr猫s la ligne de vente. Les options ont 茅t茅 accord茅es dans le cadre du plan omnibus de la soci茅t茅, la p茅riode d'acquisition (vesting) a commenc茅 le 12/02/2020 et elles sont exer莽ables jusqu'au 11/02/2029. Sont 茅galement incluses 30,1294 actions provenant du plan d'achat d'actions pour les employ茅s.
Sandra D. van der Vaart, als EVP, Chief Legal Officer von Labcorp Holdings Inc. (LH) benannt, meldete ausgleichende Optionsaus眉bungs- und Aktienverkaufstransaktionen dated 13.08.2025. Sie 眉bte 3.903 nicht qualifizierte Aktienoptionen mit einem Aus眉bungspreis von $131,43 je Aktie aus und erwarb damit 3.903 Stammaktien. Am selben Tag verkaufte sie 3.903 Stammaktien zu einem gemeldeten Preis von $271,4249 je Aktie. Die Meldung weist 6.176,6691 beg眉nstigt gehaltene Aktien nach der Erwerbszeile und 2.273,6691 Aktien nach der Verkaufszeile aus. Die Optionen wurden im Rahmen des Omnibus-Plans des Unternehmens gew盲hrt, das Vesting begann am 12.02.2020 und die Optionen sind bis zum 11.02.2029 aus眉bbar. Zus盲tzlich wurden 30,1294 Aktien aus dem Mitarbeiter-Aktienkaufplan einbezogen.
FAQ
What transactions did Sandra D. van der Vaart report on the Form 4 for Labcorp (LH)?
How many Labcorp (LH) shares does the filing show were beneficially owned after the transactions?
Were the exercised options fully vested and what are their key dates?
Did the Form 4 mention any adjustments related to corporate actions?
Did the filing include shares from an employee purchase plan?
